Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphatic Vessels | 26 | 2022 | 358 | 5.650 |
Why?
|
Lymphatic System | 18 | 2024 | 254 | 4.060 |
Why?
|
Lymphatic Metastasis | 22 | 2024 | 2943 | 3.170 |
Why?
|
Lymph Nodes | 19 | 2024 | 3486 | 2.920 |
Why?
|
Lymph | 6 | 2021 | 77 | 1.220 |
Why?
|
Lymphangiogenesis | 8 | 2016 | 172 | 1.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 6 | 2009 | 119 | 0.970 |
Why?
|
Capillary Permeability | 4 | 2017 | 768 | 0.940 |
Why?
|
Lymphedema | 4 | 2023 | 524 | 0.860 |
Why?
|
Vascular Endothelial Growth Factor C | 9 | 2015 | 127 | 0.830 |
Why?
|
Cell Tracking | 2 | 2021 | 138 | 0.810 |
Why?
|
Lymphatic Diseases | 2 | 2013 | 319 | 0.760 |
Why?
|
Neoplasms | 17 | 2024 | 22072 | 0.700 |
Why?
|
Receptors, Chemokine | 3 | 2018 | 655 | 0.630 |
Why?
|
Vasoconstriction | 2 | 2018 | 593 | 0.630 |
Why?
|
Neoplasms, Experimental | 3 | 2021 | 1229 | 0.620 |
Why?
|
Blood Vessels | 4 | 2018 | 1112 | 0.610 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 7 | 2017 | 544 | 0.600 |
Why?
|
Neoplasm Seeding | 1 | 2018 | 84 | 0.600 |
Why?
|
Nitric Oxide Synthase Type II | 2 | 2018 | 514 | 0.580 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2021 | 938 | 0.550 |
Why?
|
Neovascularization, Pathologic | 6 | 2015 | 2640 | 0.550 |
Why?
|
Models, Biological | 9 | 2022 | 9467 | 0.530 |
Why?
|
Tumor Microenvironment | 4 | 2024 | 3844 | 0.520 |
Why?
|
Green Fluorescent Proteins | 1 | 2021 | 2057 | 0.500 |
Why?
|
Patient Positioning | 1 | 2018 | 327 | 0.490 |
Why?
|
Angiopoietins | 1 | 2015 | 85 | 0.490 |
Why?
|
Endothelial Cells | 6 | 2019 | 3539 | 0.470 |
Why?
|
Animals | 60 | 2024 | 167963 | 0.470 |
Why?
|
Mice | 44 | 2024 | 81208 | 0.440 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2018 | 733 | 0.440 |
Why?
|
Anesthetics | 1 | 2019 | 522 | 0.440 |
Why?
|
Melanoma, Experimental | 4 | 2018 | 562 | 0.390 |
Why?
|
Angiogenesis Inhibitors | 6 | 2017 | 2049 | 0.380 |
Why?
|
Heart Neoplasms | 1 | 2015 | 360 | 0.380 |
Why?
|
Radiation Tolerance | 1 | 2013 | 480 | 0.380 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 694 | 0.380 |
Why?
|
Immune System | 2 | 2013 | 798 | 0.370 |
Why?
|
Lymphography | 6 | 2019 | 188 | 0.370 |
Why?
|
Fibrosarcoma | 3 | 2015 | 308 | 0.350 |
Why?
|
Immunotherapy | 3 | 2024 | 4642 | 0.350 |
Why?
|
Tumor Escape | 2 | 2024 | 370 | 0.340 |
Why?
|
Extracellular Fluid | 3 | 2022 | 165 | 0.320 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2015 | 801 | 0.310 |
Why?
|
Microscopy | 4 | 2022 | 885 | 0.300 |
Why?
|
Anesthesia | 1 | 2019 | 1584 | 0.300 |
Why?
|
Breast Neoplasms | 6 | 2023 | 21025 | 0.290 |
Why?
|
Contrast Media | 2 | 2018 | 5305 | 0.280 |
Why?
|
Head and Neck Neoplasms | 2 | 2015 | 2882 | 0.270 |
Why?
|
Inflammation Mediators | 1 | 2015 | 1881 | 0.260 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 1660 | 0.260 |
Why?
|
Endothelial Growth Factors | 3 | 2002 | 673 | 0.250 |
Why?
|
Tomography, Optical Coherence | 4 | 2021 | 2884 | 0.250 |
Why?
|
Mice, Nude | 9 | 2019 | 3607 | 0.230 |
Why?
|
Cell Survival | 3 | 2021 | 5797 | 0.220 |
Why?
|
Colonic Neoplasms | 1 | 2015 | 2526 | 0.220 |
Why?
|
Diphtheria Toxin | 1 | 2004 | 252 | 0.210 |
Why?
|
Reperfusion | 1 | 2004 | 271 | 0.210 |
Why?
|
Enzyme Precursors | 1 | 2003 | 174 | 0.210 |
Why?
|
Cell Line, Tumor | 7 | 2021 | 16939 | 0.210 |
Why?
|
Biological Transport | 2 | 2017 | 2086 | 0.210 |
Why?
|
Antineoplastic Agents | 4 | 2019 | 13630 | 0.200 |
Why?
|
Saponins | 1 | 2021 | 50 | 0.200 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 367 | 0.200 |
Why?
|
Quinazolines | 1 | 2008 | 1363 | 0.200 |
Why?
|
Mice, Inbred C57BL | 14 | 2021 | 22023 | 0.190 |
Why?
|
Osteolysis, Essential | 2 | 2013 | 30 | 0.180 |
Why?
|
Cell Movement | 5 | 2021 | 5206 | 0.180 |
Why?
|
Muscle Cells | 2 | 2019 | 195 | 0.180 |
Why?
|
Stress, Mechanical | 2 | 2015 | 1666 | 0.180 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2017 | 3484 | 0.180 |
Why?
|
Nitric Oxide Synthase Type III | 4 | 2013 | 704 | 0.180 |
Why?
|
Antibodies, Monoclonal | 6 | 2017 | 9185 | 0.180 |
Why?
|
Lung Neoplasms | 5 | 2015 | 13262 | 0.170 |
Why?
|
Piperidines | 1 | 2008 | 1650 | 0.170 |
Why?
|
Antigens, Ly | 2 | 2017 | 292 | 0.170 |
Why?
|
Microcirculation | 2 | 2018 | 1278 | 0.170 |
Why?
|
Humans | 48 | 2024 | 760621 | 0.160 |
Why?
|
Leukocytes | 3 | 2018 | 2026 | 0.160 |
Why?
|
Doppler Effect | 1 | 2018 | 12 | 0.150 |
Why?
|
In Situ Nick-End Labeling | 2 | 2018 | 613 | 0.150 |
Why?
|
Toll-Like Receptors | 1 | 2021 | 590 | 0.150 |
Why?
|
Monocytes | 2 | 2017 | 2575 | 0.150 |
Why?
|
Indocyanine Green | 1 | 2019 | 236 | 0.150 |
Why?
|
Endothelium, Vascular | 5 | 2007 | 4433 | 0.150 |
Why?
|
Laser Therapy | 1 | 2024 | 1089 | 0.140 |
Why?
|
Adaptive Immunity | 1 | 2021 | 726 | 0.140 |
Why?
|
Arm | 1 | 2019 | 583 | 0.140 |
Why?
|
Glycoproteins | 4 | 2009 | 2208 | 0.140 |
Why?
|
Hydrodynamics | 1 | 2017 | 167 | 0.130 |
Why?
|
Adjuvants, Immunologic | 1 | 2021 | 1039 | 0.130 |
Why?
|
Lithium | 1 | 2019 | 596 | 0.130 |
Why?
|
Zebrafish Proteins | 2 | 2013 | 1006 | 0.130 |
Why?
|
Taxoids | 1 | 2019 | 669 | 0.130 |
Why?
|
Germinal Center | 1 | 2018 | 379 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2018 | 4024 | 0.130 |
Why?
|
Microscopy, Fluorescence | 3 | 2018 | 2651 | 0.130 |
Why?
|
Mice, Inbred BALB C | 3 | 2021 | 6216 | 0.130 |
Why?
|
Luminescent Proteins | 1 | 2018 | 835 | 0.120 |
Why?
|
Nanoparticles | 3 | 2021 | 1943 | 0.120 |
Why?
|
Cytosol | 1 | 2018 | 887 | 0.120 |
Why?
|
Monitoring, Immunologic | 1 | 2015 | 98 | 0.120 |
Why?
|
Stress, Physiological | 2 | 2019 | 1398 | 0.120 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2015 | 100 | 0.120 |
Why?
|
Immune Tolerance | 1 | 2023 | 2299 | 0.120 |
Why?
|
Leukocyte Count | 1 | 2018 | 1600 | 0.110 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2013 | 24 | 0.110 |
Why?
|
Phosphoproteins | 1 | 2003 | 2440 | 0.110 |
Why?
|
Pressure | 3 | 2022 | 1156 | 0.110 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2015 | 474 | 0.110 |
Why?
|
Neoplasm Metastasis | 3 | 2014 | 4902 | 0.110 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2017 | 1544 | 0.110 |
Why?
|
Hemodynamics | 1 | 2024 | 4174 | 0.110 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2003 | 2418 | 0.110 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 478 | 0.110 |
Why?
|
Nitric Oxide | 6 | 2019 | 2141 | 0.110 |
Why?
|
Lymphocytes | 1 | 2021 | 2611 | 0.110 |
Why?
|
Hyaluronic Acid | 2 | 2014 | 482 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1056 | 0.110 |
Why?
|
Neoplasm Transplantation | 4 | 2009 | 2014 | 0.110 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3618 | 0.100 |
Why?
|
Neutropenia | 1 | 2018 | 884 | 0.100 |
Why?
|
Receptors, CXCR4 | 1 | 2017 | 728 | 0.100 |
Why?
|
Protective Agents | 1 | 2013 | 150 | 0.100 |
Why?
|
Oxazolone | 1 | 2011 | 61 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 1 | 2008 | 5643 | 0.100 |
Why?
|
Microbial Sensitivity Tests | 1 | 2018 | 1949 | 0.090 |
Why?
|
Immune Evasion | 1 | 2015 | 362 | 0.090 |
Why?
|
Models, Animal | 1 | 2018 | 2117 | 0.090 |
Why?
|
Liver | 3 | 2022 | 7509 | 0.090 |
Why?
|
Mastectomy | 1 | 2019 | 1832 | 0.090 |
Why?
|
Signal Transduction | 5 | 2015 | 23376 | 0.090 |
Why?
|
Female | 20 | 2023 | 391270 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4550 | 0.090 |
Why?
|
Membrane Transport Proteins | 4 | 2009 | 1035 | 0.090 |
Why?
|
Chemokines | 1 | 2015 | 962 | 0.090 |
Why?
|
Neutrophils | 3 | 2018 | 3767 | 0.090 |
Why?
|
Cell Division | 5 | 2006 | 4463 | 0.090 |
Why?
|
Lymphotoxin-alpha | 1 | 2010 | 94 | 0.090 |
Why?
|
Bone Marrow Cells | 2 | 2011 | 2414 | 0.090 |
Why?
|
Mice, Inbred C3H | 3 | 2016 | 915 | 0.090 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 1975 | 0.090 |
Why?
|
Zebrafish | 3 | 2013 | 2997 | 0.090 |
Why?
|
Immunohistochemistry | 3 | 2018 | 11071 | 0.090 |
Why?
|
Deoxycytidine | 1 | 2014 | 873 | 0.090 |
Why?
|
Receptors, Growth Factor | 2 | 2001 | 326 | 0.080 |
Why?
|
Fluorescence Recovery After Photobleaching | 1 | 2009 | 53 | 0.080 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2023 | 3075 | 0.080 |
Why?
|
Prognosis | 3 | 2021 | 29658 | 0.080 |
Why?
|
Muscle Contraction | 3 | 2019 | 1201 | 0.080 |
Why?
|
Kinetics | 2 | 2019 | 6377 | 0.080 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2014 | 741 | 0.080 |
Why?
|
B-Lymphocytes | 2 | 2021 | 4742 | 0.080 |
Why?
|
Pyrroles | 1 | 2015 | 1137 | 0.080 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1189 | 0.080 |
Why?
|
Cell Physiological Phenomena | 1 | 2009 | 150 | 0.080 |
Why?
|
Diagnostic Imaging | 2 | 2014 | 3527 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2023 | 10181 | 0.070 |
Why?
|
Lymphangiosarcoma | 1 | 2006 | 14 | 0.070 |
Why?
|
Mice, Knockout | 5 | 2017 | 14372 | 0.070 |
Why?
|
Indoles | 1 | 2015 | 1829 | 0.070 |
Why?
|
DNA Primers | 2 | 2008 | 2819 | 0.070 |
Why?
|
Cells, Cultured | 3 | 2018 | 18957 | 0.070 |
Why?
|
Inflammation | 3 | 2018 | 10756 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2021 | 5799 | 0.060 |
Why?
|
Skin | 3 | 2011 | 4466 | 0.060 |
Why?
|
Meningeal Neoplasms | 1 | 2015 | 1249 | 0.060 |
Why?
|
Neurofibromatosis 2 | 1 | 2009 | 385 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2006 | 256 | 0.060 |
Why?
|
Receptors, Notch | 1 | 2010 | 743 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10827 | 0.060 |
Why?
|
Neuroma, Acoustic | 1 | 2009 | 459 | 0.060 |
Why?
|
Cell Cycle | 1 | 2013 | 2934 | 0.060 |
Why?
|
Microscopy, Confocal | 2 | 2009 | 1972 | 0.060 |
Why?
|
Melanoma | 3 | 2021 | 5697 | 0.060 |
Why?
|
Enzyme Inhibitors | 2 | 2013 | 3726 | 0.060 |
Why?
|
Microvessels | 2 | 2024 | 572 | 0.060 |
Why?
|
DNA Damage | 1 | 2013 | 2442 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2001 | 1613 | 0.050 |
Why?
|
Homeostasis | 1 | 2014 | 3306 | 0.050 |
Why?
|
Mammary Neoplasms, Experimental | 2 | 2009 | 507 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18137 | 0.050 |
Why?
|
Chemokine CCL21 | 1 | 2003 | 50 | 0.050 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2014 | 1724 | 0.050 |
Why?
|
Endothelium, Lymphatic | 1 | 2003 | 63 | 0.050 |
Why?
|
Vesicular Transport Proteins | 2 | 2002 | 374 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2002 | 64 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5253 | 0.050 |
Why?
|
Receptors, Angiotensin | 1 | 2022 | 141 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2017 | 6131 | 0.050 |
Why?
|
Hearing Loss | 1 | 2009 | 780 | 0.050 |
Why?
|
Angiotensins | 1 | 2022 | 143 | 0.050 |
Why?
|
Chemokines, CC | 1 | 2003 | 283 | 0.050 |
Why?
|
Genes, Homeobox | 1 | 2003 | 284 | 0.050 |
Why?
|
Lower Extremity | 2 | 2022 | 1194 | 0.050 |
Why?
|
Nitric Oxide Synthase | 1 | 2004 | 908 | 0.050 |
Why?
|
Male | 16 | 2023 | 359744 | 0.050 |
Why?
|
Microscopy, Atomic Force | 1 | 2002 | 247 | 0.050 |
Why?
|
Extracellular Matrix | 1 | 2009 | 1726 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 5961 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14495 | 0.050 |
Why?
|
PPAR gamma | 1 | 2023 | 484 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 2 | 2016 | 4048 | 0.050 |
Why?
|
Losartan | 1 | 2022 | 265 | 0.040 |
Why?
|
Collagen | 1 | 2009 | 2636 | 0.040 |
Why?
|
Extracellular Space | 1 | 2002 | 564 | 0.040 |
Why?
|
Models, Theoretical | 2 | 2024 | 3562 | 0.040 |
Why?
|
Transplantation, Heterologous | 2 | 2009 | 2379 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 2009 | 1152 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11152 | 0.040 |
Why?
|
Calcium | 3 | 2019 | 5725 | 0.040 |
Why?
|
Oxygen | 2 | 2022 | 4193 | 0.040 |
Why?
|
Arteriovenous Malformations | 1 | 2003 | 397 | 0.040 |
Why?
|
Lung | 1 | 2018 | 9994 | 0.040 |
Why?
|
Precancerous Conditions | 1 | 2006 | 977 | 0.040 |
Why?
|
Arteries | 1 | 2024 | 1126 | 0.040 |
Why?
|
Equipment Design | 2 | 2009 | 3520 | 0.040 |
Why?
|
Veins | 1 | 2003 | 765 | 0.040 |
Why?
|
Osmolar Concentration | 1 | 2019 | 660 | 0.040 |
Why?
|
Orchiectomy | 1 | 2000 | 470 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 11712 | 0.040 |
Why?
|
Rats, Wistar | 1 | 2021 | 1850 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6465 | 0.040 |
Why?
|
Edema | 1 | 2022 | 769 | 0.040 |
Why?
|
Antigens, Surface | 1 | 2002 | 1608 | 0.040 |
Why?
|
Gold | 1 | 2021 | 484 | 0.040 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2000 | 412 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2010 | 2873 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6853 | 0.040 |
Why?
|
Apoptosis | 1 | 2013 | 9501 | 0.040 |
Why?
|
Lasers | 1 | 2002 | 952 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2018 | 193 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 8986 | 0.040 |
Why?
|
Chemokine CX3CL1 | 1 | 2017 | 64 | 0.040 |
Why?
|
omega-N-Methylarginine | 2 | 2009 | 108 | 0.040 |
Why?
|
Base Sequence | 1 | 2008 | 12446 | 0.040 |
Why?
|
Tail | 2 | 2009 | 92 | 0.030 |
Why?
|
Mice, SCID | 4 | 2004 | 2627 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2042 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2014 | 5351 | 0.030 |
Why?
|
Benzylamines | 1 | 2017 | 248 | 0.030 |
Why?
|
Drainage | 1 | 2022 | 1161 | 0.030 |
Why?
|
Homeodomain Proteins | 2 | 2003 | 2414 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 247 | 0.030 |
Why?
|
Ear, External | 1 | 2016 | 164 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 1998 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 2 | 2003 | 2802 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2017 | 454 | 0.030 |
Why?
|
Pulsatile Flow | 1 | 2016 | 321 | 0.030 |
Why?
|
Macaca mulatta | 1 | 2021 | 2316 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2002 | 3094 | 0.030 |
Why?
|
Capillaries | 1 | 2018 | 744 | 0.030 |
Why?
|
Video Recording | 1 | 2019 | 955 | 0.030 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2016 | 266 | 0.030 |
Why?
|
Perfusion | 1 | 2019 | 1376 | 0.030 |
Why?
|
Receptor, TIE-2 | 1 | 2013 | 176 | 0.030 |
Why?
|
Androgens | 1 | 2000 | 1291 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2003 | 2895 | 0.030 |
Why?
|
Neuroprotective Agents | 1 | 2019 | 961 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2001 | 1931 | 0.020 |
Why?
|
Mycoplasma pulmonis | 1 | 2010 | 2 | 0.020 |
Why?
|
Algorithms | 3 | 2019 | 13981 | 0.020 |
Why?
|
Adult | 5 | 2019 | 219994 | 0.020 |
Why?
|
Lymphotoxin-beta | 1 | 2010 | 14 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20509 | 0.020 |
Why?
|
Rats | 2 | 2021 | 23711 | 0.020 |
Why?
|
Mycoplasma Infections | 1 | 2010 | 120 | 0.020 |
Why?
|
Stem Cells | 1 | 2003 | 3523 | 0.020 |
Why?
|
Bone Resorption | 1 | 2013 | 720 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 11903 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2015 | 58995 | 0.020 |
Why?
|
Aged | 3 | 2019 | 169152 | 0.020 |
Why?
|
Neuropilin-2 | 1 | 2009 | 55 | 0.020 |
Why?
|
Middle Aged | 4 | 2019 | 220352 | 0.020 |
Why?
|
Drug Synergism | 1 | 2013 | 1754 | 0.020 |
Why?
|
Neuropilin-1 | 1 | 2009 | 90 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2001 | 2299 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1895 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 4353 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2648 | 0.020 |
Why?
|
Subcutaneous Tissue | 1 | 2009 | 132 | 0.020 |
Why?
|
Integrin beta Chains | 1 | 2009 | 115 | 0.020 |
Why?
|
Relaxin | 1 | 2009 | 42 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2017 | 10446 | 0.020 |
Why?
|
Image Enhancement | 2 | 2009 | 2881 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2007 | 3775 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2009 | 384 | 0.020 |
Why?
|
Up-Regulation | 1 | 2017 | 4122 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 3442 | 0.020 |
Why?
|
Diffusion | 1 | 2009 | 813 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 3602 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2019 | 80372 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2001 | 666 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5201 | 0.020 |
Why?
|
Chickens | 1 | 2009 | 860 | 0.020 |
Why?
|
Embryo, Nonmammalian | 1 | 2010 | 900 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2019 | 3340 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2002 | 14660 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2009 | 1753 | 0.020 |
Why?
|
Chylothorax | 1 | 2006 | 83 | 0.020 |
Why?
|
Hydrostatic Pressure | 1 | 2006 | 95 | 0.020 |
Why?
|
Collagen Type I | 1 | 2009 | 616 | 0.020 |
Why?
|
Microscopy, Video | 1 | 2006 | 242 | 0.020 |
Why?
|
Immunization | 1 | 2010 | 1227 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2001 | 4319 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2003 | 11481 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3584 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6828 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2002 | 6315 | 0.010 |
Why?
|
Fluorescein Angiography | 1 | 2009 | 1045 | 0.010 |
Why?
|
Databases, Factual | 1 | 2019 | 8035 | 0.010 |
Why?
|
Infusion Pumps, Implantable | 1 | 2004 | 157 | 0.010 |
Why?
|
Ligation | 1 | 2004 | 448 | 0.010 |
Why?
|
Stromal Cells | 1 | 2009 | 1326 | 0.010 |
Why?
|
Rheology | 1 | 2004 | 348 | 0.010 |
Why?
|
Crosses, Genetic | 1 | 2004 | 751 | 0.010 |
Why?
|
Organ Specificity | 1 | 2007 | 1955 | 0.010 |
Why?
|
Hyperplasia | 1 | 2006 | 1155 | 0.010 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2006 | 491 | 0.010 |
Why?
|
Time Factors | 2 | 2017 | 40165 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2006 | 1832 | 0.010 |
Why?
|
Embryonic Stem Cells | 1 | 2009 | 1262 | 0.010 |
Why?
|
Partial Pressure | 1 | 2000 | 245 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2017 | 8950 | 0.010 |
Why?
|
Oncogenes | 1 | 2006 | 1220 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 12531 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2009 | 2864 | 0.010 |
Why?
|
Neurons | 1 | 2019 | 9426 | 0.010 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2010 | 3604 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4573 | 0.010 |
Why?
|
Luminescent Measurements | 1 | 2000 | 378 | 0.010 |
Why?
|
Fibroblasts | 1 | 2009 | 4090 | 0.010 |
Why?
|
Adolescent | 3 | 2015 | 87810 | 0.010 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2000 | 278 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18416 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41335 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13502 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2009 | 9530 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2006 | 2828 | 0.010 |
Why?
|
Necrosis | 1 | 2000 | 1612 | 0.010 |
Why?
|
Kidney | 1 | 2010 | 7064 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2000 | 2221 | 0.010 |
Why?
|
Genotype | 1 | 2009 | 12960 | 0.010 |
Why?
|
Down-Regulation | 1 | 2001 | 2913 | 0.010 |
Why?
|
Glioblastoma | 1 | 2009 | 3484 | 0.010 |
Why?
|
Oxygen Consumption | 1 | 2000 | 1843 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2007 | 7593 | 0.010 |
Why?
|
Cell Communication | 1 | 2001 | 1653 | 0.010 |
Why?
|
Doxorubicin | 1 | 2000 | 2209 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2010 | 7850 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2015 | 39261 | 0.010 |
Why?
|
Cell Line | 1 | 2006 | 15620 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 42063 | 0.010 |
Why?
|
Brain | 1 | 2019 | 26951 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2007 | 9411 | 0.010 |
Why?
|
Phenotype | 1 | 2009 | 16546 | 0.010 |
Why?
|
RNA | 1 | 2001 | 2722 | 0.010 |
Why?
|
Blood Pressure | 1 | 2004 | 8525 | 0.000 |
Why?
|
Treatment Outcome | 1 | 2015 | 65017 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36290 | 0.000 |
Why?
|
Child | 1 | 2015 | 79806 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2001 | 8515 | 0.000 |
Why?
|
Young Adult | 1 | 2009 | 58741 | 0.000 |
Why?
|